previous arrow
next arrow
Slider

yourgene health logo RGB

Yourgene Health plc
(“Yourgene”, the “Company” or the “Group”)

Half-year Results

Manchester, UK – 3 December 2018: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its unaudited half-year results for the six months ended 30 September 2018.

Financial highlights

•    Revenues increased by 45% to £3.9m (H1 2017-18: £2.7m)
•    Gross profit up 49% to £2.0m (H1 2017-18: £1.3m)
•    General administrative expenses down 4% to £4.4m (H1 2017-18: £4.5m)
     o    Expenses excluding depreciation and amortisation down to £3.8m (H1 2017-18: £4.1m)
     o    Further £1m annualised cost reduction being implemented
•    Operating loss reduced by 46% to £2.5m (H1 2017-18: £4.7m)
•    Loss before tax reduced by 30% to £3.5m (H1 2017-18: £4.9m)
•    Cash used by operations reduced by 25% to £3.2m (H1 2017-18: £4.3m)
•    Cash and cash equivalents at 30 September 2018 of £0.2m (31 March 2018: £0.3m)
•    Post period-end, in October 2018, completed a £3.1m equity raise

Operational highlights

•    Test volumes increased by 73% to 38,000 (H1 2017-18: 22,000)
•    Entered into a legal settlement and licence agreement with Illumina, ending all patent litigation
     o    Development of the Illumina-based IONA® test progressing well and on schedule
•    Appointment of Mr Lyn Rees as Chief Executive Officer
•    Appointment of Mr Hayden Jeffreys as Group Commercial Director
•    Significant commercial progress achieved, including:
     o    Continued to expand international footprint in both existing and new territories with laboratories added in Africa and Asia
     o    A 3-year agreement signed with one of India’s leading diagnostics groups to offer mass-population non-invasive prenatal testing (“NIPT”) screening
     o    Secured an agreement with Coastal Genomics to develop advanced technologies for clinical DNA sequencing tests
     o    Entered into a partnership with Abnova to collaborate on the development of next generation sequencing (“NGS”) capabilities for single cell analysis
•    Post period-end
     o    Announced a $1m collaboration agreement between Yourgene Bioscience and a leading clinical research organisation in Taiwan to deliver NGS testing in oncology
     o    Changed the Group’s name to Yourgene Health plc, to reflect the Group's broadened product development ambitions and research service capabilities

Lyn Rees, Chief Executive Officer of Yourgene, commented:

“We are making excellent commercial progress, with revenues and test volumes up by 45% and 73% respectively in the first half, with costs and cash consumption reducing rapidly.  

“We continued to grow our customer base successfully outside of the IP-restricted markets for NIPT in the period, and now have product and service sales in over 20 global territories. With market access now clear post the settlement with Illumina, we will look to broaden our international reach with a refreshed and upskilled commercial structure. As well as bringing new customers to the business, we are excited to rapidly expand existing markets such as India, the Middle East, Africa and South East Asia where the foundations for growth have been laid.

We are also implementing a rapid reorientation of the business towards strategic growth drivers in line with my initial goals for the business, and I believe we now have a very significant opportunity ahead of us. I look forward to providing further updates as we leverage our redefined structure and industry leading technical capabilities to offer contract development services, develop our product portfolio and accelerate growth and geographic expansion.”
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:
    
Yourgene Health plc
Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it. 
Tel: +44 (0)161 667 1053

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie
Tel: +44 (0)20 7213 0880

finnCap (Broker)
Geoff Nash / Matthew Radley (Corporate Finance)
Tim Redfern (Corporate Broking)
Tel: +44 (0)20 7220 0500

Vigo Communications
Ben Simons / Fiona Henson / Antonia Pollock
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0)20 7390 0238

About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.  

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions.

Yourgene Health’s first commercialised products are non-invasive prenatal tests (NIPT) for Down’s syndrome and other genetic disorders, targeting a share of an emerging billion-dollar global market.

Prenatal screening is an established clinical practice, but accuracy challenges with traditional methods are driving the need for NIPT and other DNA-based reproductive health testing solutions. Yourgene Health’s customer-focused products and services support all types of customer, irrespective of size, geography and market maturity. Our commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Through our technical expertise and partnerships, Yourgene Health is aiming to extend its genetic testing offering into complementary areas of reproductive health and oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore. For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

  • 16 August 2019 - Directorate Change Appointment of business development sector specialist as Non-executive Director +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Directorate Change

    Appointment of business development sector specialist as Non-executive Director 

    Manchester, UK – 16 August 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the appointment of Jonathan Seaton to the Board of Directors as a Non-executive Director, with immediate effect .

    Jonathan has extensive experience working for leading global life sciences and diagnostic companies having worked on more than 40 M&A transactions as well as strategic

    Read More
  • 29 July 2019 - Appointment of Director +

    Yourgene Health plc

    (“ Yourgene ”, the “ Company ” or the “ Group ”)

    Appointment of Director

    Manchester, UK – 29 July 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces the appointment of Dr John Brown CBE to the Board of Directors as a Non-executive Director with immediate effect.   Dr Brown will act as the Senior Independent Director on the Board.

    Dr Brown

    Read More
  • 10 July 2019 - Results for the Year Ended 31 March 2019, 
Business Update and Director Change +

    Yourgene Health plc

    (“ Yourgene ” or the “ Company ” or the “ Group ”)

    Results for the Year Ended 31 March 2019,
    Business Update and Director Change

      Manchester, UK – 10 July 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its results for the year ended 31 March 2019, and provides a business update.

    Full year results summary :

    • Comprehensive profit of

    Read More
  • 24 June 2019 - Yourgene participates in key global conferences +

    Yourgene Health plc
    (“Yourgene Health” or the "Company")

    Yourgene participates in key global conferences

    Manchester, UK - 24 June 2019: Yourgene Health (AIM : YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its participation at key conferences to raise the profile of its reproductive health products and services.

    European Society Human Genetics

    Yourgene recently attended the European Human Genetics Conference, organised by the European Society of Human Genetics. The event – held

    Read More
  • 25 April 2019 - Completion of Acquisition +

    THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR PUBLIC RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS DOCUMENT.

    Yourgene Health plc
    (“Yourgene” or the “Company”)

    Read More
  • 17 April 2019 - Proposed acquisition of Delta Diagnostics (UK) Limited +

    Yourgene Health plc
    (“Yourgene” or the “Company”)

    Proposed acquisition of Delta Diagnostics (UK) Limited ("Elucigene")
    and
    Proposed placing of a minimum of 92,682,928new Ordinary Shares
    and
    Proposed subscription for 4,878,048new Ordinary Shares

    Highlights

    ● Proposed acquisition of Elucigene, a leading molecular diagnostics manufacturer and developer, complementary to Yourgene’s current and planned product offering

    ●  Acquisition consideration of £9.2 million (comprising £6.3 million cash and £2.9 million equity), includes £0.4 million of net cash, representing an enterprise

    Read More
  • 8 April 2019 - Full-year Trading Update +

    Yourgene Health plc

    (“Yourgene”, the “Company” or the “Group”)

    Full-year Trading Update

    Manchester, UK 8 April 2019 : Yourgene Health (AIM : YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces a trading update for the year ended 31 March 2019.

    Trading Highlights

    ●  Unaudited revenues were ahead of market expectations, increasing by 45% to over £8.9m (2018: £6.1m), with growth in all active regions
    ●  Test volumes increased by 67% to

    Read More
  • 25 March 2019 - Yourgene raises IONA® test awareness in Egypt with British Ambassador (2) +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Yourgene raises IONA® test awareness in Egypt with British Ambassador

    Manchester, UK 25 March 2019 : Yourgene Health ( AIM : YGEN ) , the international molecular diagnostics group which commercialises genetic products and services, has held an event in Egypt to raise awareness of the IONA® test, a non-invasive prenatal DNA test for Down’s syndrome, amongst the clinical community.

    The event was attended by His Excellency Sir Geoffrey Adams, the British

    Read More
  • 18 February 2019 - Yourgene Health Announces Capital and Commercial Restructuring with Major Shareholder +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Yourgene Health Announces Capital and Commercial Restructuring

    with Major Shareholder

    Manchester, UK – 18 February 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces a restructuring of its financial and commercial relationship with Life Technologies Limited (“Life Technologies”).

    Lyn Rees, CEO of Yourgene Health, commented:

    “I am delighted with the restructuring of our relationship with Life Technologies, which places Yourgene

    Read More
  • 8 January 2019 - High throughput NIPT solution for clinical laboratories +

    Yourgene Health plc
    (“Yourgene”, the “Company”)
     
    Yourgene launches Sage™ 32 plex
     
    High throughput NIPT solution for clinical laboratories
     
    Manchester, UK – 8 January 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, is pleased to announce the launch of the Sage™ 32 plex test, a new high throughput non-invasive prenatal testing (“NIPT”) and analysis solution for clinical laboratories. 
     
    Sage™ 32 plex uses the latest
    Read More
  • 3 December 2018 - Half-year Results +

    yourgene health logo RGB

    Yourgene Health plc
    (“Yourgene”, the “Company” or the “Group”)

    Half-year Results

    Manchester, UK – 3 December 2018: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its unaudited half-year results for the six months ended 30 September 2018.

    Financial highlights

    •    Revenues increased by 45% to £3.9m (H1 2017-18: £2.7m)
    •    Gross profit up 49% to £2.0m (H1 2017-18: £1.3m)
    •    General administrative expenses down 4% to

    Read More
  • 7 November 2018 - Change of Name to Yourgene Health plc & Change of Website Address +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Change of Name to Yourgene Health plc
    &
    Change of Website Address

    Manchester, UK – 7 November 2018: Premaitha Health plc, the international molecular diagnostics group which commercialises genetic products and services that positively impact human health, is pleased to confirm the renaming of the Group as Yourgene Health plc (“Yourgene Health”).

    Further to the special resolution approved at the Group’s Annual General Meeting on 25 October 2018,

    Read More
  • 12 October 2018 - Trading Update & Notice of Results +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Trading Update & Notice of Results

    Manchester, UK – 12 October 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to provide an update on trading for the six-month period ended 30 September 2018 (“H1”).

    H1 revenues were approximately £3.9 million, an increase of 45 per cent over the corresponding period last year. The Company has made a strong start to the second

    Read More
  • 04 October 2018 - $1 million collaboration agreement +

    Premaitha Health PLC
    (“Premaitha,” the “Company” or the “Group”)

    $1 million collaboration agreement
    Partnership to provide genetic testing based on next generation sequencing for oncology

    Manchester, UK – 4 October 2018: Premaitha (AIM: NIPT), a leading international molecular diagnostics group, announces a new partnership agreement between the Group’s Yourgene Bioscience division (“Yourgene”) and a leading clinical research organisation in Taiwan (the “Partner”), to deliver next generation sequencing (“NGS”) testing in oncology.

    Under the terms of

    Read More
  • 28 September 2018 - Proposed fundraise to raise approximately £2.5 million +

    THIS ANNOUNCEMENT, INCLUDING THE APPENDIX AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
Pregnant lady sitting at table with Laptop

Investor Relations
Ben Simons / Fiona Henson / Antonia Pollock
Vigo Communications
Sackville House
40 Piccadilly
London W1J 0DR
yourgene@vigocomms.com
T : +44 (0) 20 7390 0230

Two business people looking at computer screen